Scarica l'app Stockscreener
8.09
0.00%
0.00
Precedente Chiudi:
$8.09
Aprire:
$8.14
Volume 24 ore:
485.83K
Relative Volume:
0.41
Capitalizzazione di mercato:
$527.82M
Reddito:
$141.31M
Utile/perdita netta:
$-297.87M
Rapporto P/E:
-1.50
EPS:
-5.3933
Flusso di cassa netto:
$-168.20M
1 W Prestazione:
+9.92%
1M Prestazione:
-18.37%
6M Prestazione:
-9.81%
1 anno Prestazione:
-38.43%
Intervallo 1D:
$7.84
$8.28
Intervallo di 1 settimana:
$7.22
$8.28
Portata 52W:
$5.37
$17.58
Ginkgo Bioworks Holdings Inc Stock (DNA) Company Profile
Nome
Ginkgo Bioworks Holdings Inc
Settore
Industria
Telefono
(877) 442-5362
Indirizzo
27 DRYDOCK AVENUE, BOSTON
Compare DNA vs VRTX, REGN, ARGX, RVMD, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
DNA
Ginkgo Bioworks Holdings Inc
|
8.08 | 486.67M | 141.31M | -297.87M | -168.20M | -5.3933 |
VRTX
Vertex Pharmaceuticals Inc
|
477.10 | 121.57B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
762.63 | 69.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
853.82 | 55.61B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
187.53 | 39.98B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
316.01 | 33.81B | 5.76B | 514.49M | 1.10B | 4.4813 |
Ginkgo Bioworks Holdings Inc Stock (DNA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-05-15 | Downgrade | BTIG Research | Neutral → Sell |
| 2024-05-10 | Downgrade | William Blair | Mkt Perform → Underperform |
| 2023-11-14 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2023-11-09 | Downgrade | BTIG Research | Buy → Neutral |
| 2023-06-02 | Downgrade | Goldman | Neutral → Sell |
| 2023-05-11 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2022-11-29 | Iniziato | Berenberg | Buy |
| 2022-10-04 | Iniziato | Morgan Stanley | Equal-Weight |
| 2022-05-18 | Downgrade | BofA Securities | Neutral → Underperform |
| 2022-03-02 | Ripresa | Cowen | Outperform |
| 2022-02-23 | Iniziato | Goldman | Neutral |
| 2022-02-01 | Iniziato | BofA Securities | Neutral |
| 2022-01-28 | Iniziato | BofA Securities | Buy |
| 2022-01-07 | Iniziato | BTIG Research | Buy |
| 2021-11-29 | Iniziato | Jefferies | Buy |
| 2021-10-13 | Iniziato | Raymond James | Outperform |
| 2021-10-12 | Iniziato | William Blair | Outperform |
| 2021-09-20 | Iniziato | HSBC Securities | Buy |
Mostra tutto
Ginkgo Bioworks Holdings Inc Borsa (DNA) Ultime notizie
Ginkgo Bioworks Holdings Inc (DNA) Balance Sheet - TradingKey
Ginkgo Bioworks Holdings Inc (DNA) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
DNA|Ginkgo Bioworks Holdings Inc|Price:7.445|Chg%:+0.085 - TradingKey
Ginkgo Bioworks Holdings Inc (DNA) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Ginkgo Bioworks Holdings Inc (DNA) Income Statement - TradingKey
DNA|Ginkgo Bioworks Holdings Inc|Price:7.761| - TradingKey
ETFs Investing in Ginkgo Bioworks Holdings, Inc. Class A Stocks - TradingView
Ginkgo Bioworks Holdings Inc (DNA) Cash Flow - TradingKey
Ginkgo Bioworks Holdings Inc (DNA) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Ginkgo Bioworks Holdings Inc (DNA) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
DNA|Ginkgo Bioworks Holdings Inc|Price:7.360|Chg%:-0.575 - TradingKey
Responsive Playbooks and the DNA Inflection - Stock Traders Daily
Ginkgo Regains Compliance with NYSE Minimum Bid Price Requiremen - GuruFocus
Ginkgo Bioworks Holdings Inc (DNA) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Ginkgo Bioworks Holdings Inc (DNA) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Ginkgo CEO Jason Kelly: Block U.S. Investment in Chinese Biotech Before Drug Discovery Moves Entirely Offshore - finance.biggo.com
Biotech firm Ginkgo in talks with SPAC for over $20b deal - The Financial Express
Ginkgo Bioworks (NYSE: DNA) CFO logs RSU vesting and tax sell-to-cover - Stock Titan
Ginkgo Bioworks (DNA) 10K Form and Latest SEC Filings 2026 - MarketBeat
Form 144 Ginkgo Bioworks Holdings For: 17 July By Investing.com - Investing.com Nigeria
Ginkgo Bioworks (NYSE: DNA) insider Steve Coen plans Class A stock sale - Stock Titan
Ginkgo Bioworks (DNA) Slides 7.89% as Market Sentiment Turns CautiousTriple EMA - dars.gov.et
Synthetic Biology Market Set for Strong Expansion | Ginkgo - openPR.com
Ginkgo Bioworks Holdings' Stock Sinks To US$9.07, But Insiders Sold Even Lower - simplywall.st
Ginkgo Bioworks : Q1 2026 Results Presentation - marketscreener.com
DNAGinkgo Bioworks Holdings Inc Options - Finviz
Ginkgo Bioworks reports Q1 revenue decline, reaffirms cash burn - Investing.com
Most Volatile Stocks in the US (July 2026) - Investing.com
Ginkgo Bioworks Holdings Inc Warrant 2021-01.08.26 on Ginkgo Bioworks -A Financial Disclosures & SEC Filings - TradingView
How Western Biotechs Are Navigating The China Challenge - insights.citeline.com
Understanding the Setup: (DNA) and Scalable Risk - Stock Traders Daily
Ginkgo Bioworks (DNA) Holds Near $10.21 as Stock Consolidates in Tight RangeIron Condor Alert - dars.gov.et
Ginkgo Bioworks Holdings, Inc.(NYSE:DNA) dropped from Russell 3000E Growth Benchmark - marketscreener.com
Ginkgo Bioworks Holdings, Inc.(NYSE: DNA) dropped from Russell 3000 Growth Benchmark - marketscreener.com
Ginkgo Bioworks Holdings, Inc.(NYSE:DNA) dropped from Russell Microcap Growth Benchmark Index - marketscreener.com
Palantir's Bold Biosecurity Opportunity Could Be Bigger Than Investors Think - The Motley Fool
Ginkgo Bioworks (DNA) Q1 2026 Earnings: EPS Misses Estimates, Stock Surges Over 7%Buyback Announcement Report - dars.gov.et
Enterprise value to revenue forward of Ginkgo Bioworks Holdings, Inc. – NYSE:DNA - TradingView
Price to earnings forward of Ginkgo Bioworks Holdings, Inc. – NYSE:DNA - TradingView
Enterprise value to EBIT forward of Ginkgo Bioworks Holdings, Inc. – NYSE:DNA - TradingView
Enterprise value to EBITDA forward of Ginkgo Bioworks Holdings, Inc. – NYSE:DNA - TradingView
Price to sales forward of Ginkgo Bioworks Holdings, Inc. – NYSE:DNA - TradingView
Ginkgo Bioworks (DNA) Rallies 6.27% as Biotech Sector Shows Renewed StrengthInitial Balance - dars.gov.et
Ginkgo Bioworks Holdings, Inc. Class A Actuals & Estimates (NYSE:DNA) - TradingView
9L40 Forecast — Price Target — Prediction for 2027 - TradingView
Price to sales forward of Ginkgo Bioworks Holdings Inc. – OTC:DNABW - TradingView
Price to earnings forward of Ginkgo Bioworks Holdings Inc. – OTC:DNABW - TradingView
Enterprise value to EBITDA forward of Ginkgo Bioworks Holdings Inc. – OTC:DNABW - TradingView
Price to book forward of Ginkgo Bioworks Holdings Inc. – OTC:DNABW - TradingView
DNA Forecast — Price Target — Prediction for 2027 - TradingView
Ginkgo Bioworks Holdings Inc (DNA) Valuation: PE, PB & Fair Value Analysis - TradingKey
Ginkgo Bioworks Holdings Inc Azioni (DNA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.44%
0.02%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):